United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?

Zacks Premium and Style Scores - Zacks Premium offers tools like daily updates of Zacks Rank and Zacks Industry Rank, full access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens to help investors make informed decisions [1] - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, assigning ratings from A to F, with A being the best [2][3] - The Style Scores are divided into four categories: Value Score, Growth Score, Momentum Score, and VGM Score, which combines all three styles [3][4][5] - Zacks Rank, combined with Style Scores, helps investors select stocks with the highest probability of outperforming the market [6][8] - Stocks with a Zacks Rank 1 or 2 and Style Scores of A or B offer the best chance of high returns [9][10] United Therapeutics Corporation (UTHR) - United Therapeutics markets four medicines for pulmonary arterial hypertension (PAH): Remodulin, Orenitram, Tyvaso, and Adcirca [11] - UTHR has a Zacks Rank of 3 (Hold) and a VGM Score of A, with a Value Style Score of B due to attractive valuation metrics like a forward P/E ratio of 14.7 [12][13] - Four analysts revised their earnings estimates upwards for fiscal 2024, increasing the Zacks Consensus Estimate by $0.58 to$25.44 per share, with an average earnings surprise of 4.2% [12] - UTHR is a stock to watch due to its solid Zacks Rank and top-tier Value and VGM Style Scores [13][14]